WUXI BIO

2269
46.7400.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:11

Overview

WUXI BIO (2269)

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing...

Open
46.020
High
47.280
Low
45.640
Prev. Close
46.740
Volume
21.80M
Turnover
1.01B
Avg Price
46.479
Bid/Ask Ratio
-85.96%
Amplitude
3.51%
52wk High
58.000
Volume Ratio
0.72
Turnover Ratio
0.53%
52wk Low
28.480
HK Mkt Cap
192.44B
Market CapHKD
192.44B
P/ETTM
33.37
P/EDynamic
34.25
P/EStatic
--
EPSTTM
1.40
EPSDynamic
1.36
EPSStatic
--
BVPS
13.44
P/B
3.48
HK Shares
4.12B
Dividend YieldTTM
--
DividendTTM
--
Shares
4.12B
Min lot size
500
Currency
HKD

WUXI BIO Analyst Rating

View more

Forecast & Rating

Nov 9, 2026
Price forecast
HK$60.1928.78%
Forecast & RatingStrong buy
27analysts
  • Strong buy66.67%
  • Buy18.52%
  • Hold14.81%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    WuXi Biologics closed flat today, stabilizing after a 4.46% weekly decline. Year-to-date, the stock has advanced 43.64% to HK$46.74, remaining 19.41% below its 52-week peak of HK$58 recorded on October 5, 2026. Recent positive catalysts including a landmark biosimilars contract award and Citigroup's maintained buy rating support market sentiment. Q2 results demonstrate strong momentum with revenue of HK$6.81 billion growing 24.83% year-over-year and operating profit of HK$2.15 billion surging 44.25% year-over-year, indicating significant operational leverage. Net profit margin remains solid at 20.7%. However, the stock's P/E ratio of 33.37 stands at elevated levels, while the daily turnover rate of just 0.53% suggests institutional participation is limited, potentially constraining near-term price action despite strong earnings growth.

  2. Nov, 13

    The stock declined approximately 4.4% to HK$46.74 today, primarily driven by profit-taking following the prior strength fueled by biosimilar deal announcements and institutional rating upgrades. Morning session opened at HK$48.4, peaked at HK$49.12 around 9:36 AM, then retreated to close at HK$47.46; afternoon trading extended losses, reaching an intraday low of HK$46.38 at 3:47 PM before settling at HK$46.74. The stock has appreciated 43.64% year-to-date from HK$32.54, currently trading 19.4% below its 52-week high of HK$58, hovering near the 20-day moving average of HK$47.02. Recent quarterly results showed resilience: Q2 revenue reached HK$6.81 billion, up 24.83% year-over-year, while operating profit surged 44.25% to HK$2.15 billion with net margin stable at 20.7%. At a market capitalization of approximately HK$192.4 billion and a P/E multiple of 33.4, valuations appear fairly positioned relative to the strong momentum in its biotech drug and biosimilar services franchises.

  3. Nov, 12

    WuXi Biologics (2269.HK) witnessed significant intraday volatility today, opening lower at 47.98 HKD before sliding to an intraday low of 47.62 HKD, then rebounding sharply to a high of 49.94 HKD (up 2.2% from previous close) as the market embraced recent positive catalysts including Fresenius' exclusive development partnership to expand biosimilar pipeline, Citi's maintained buy rating with the stock added to 4Q guidance-uplift catalyst watch, and Hong Kong ESG awards recognition. However, afternoon profit-taking amid broader market weakness (HSI down ~1%) pulled the stock back to close flat at 48.88 HKD. Financial fundamentals remain solid with Q2 revenue of 68.07B HKD (+25% YoY) and operating profit of 21.53B HKD (+44% YoY), demonstrating accelerating profit margin expansion. The stock has surged 50% year-to-date and sits near its 52-week high of 58 HKD (only 15.7% below), trading well above its 20-day moving average, though a P/E multiple of 34.9 leaves limited valuation cushion.

  4. Nov, 11

    Shares declined approximately 1.5% as Hong Kong's broader market retreated nearly 1%, with the Hang Seng Index recording notable losses. Intraday action revealed sharp volatility: morning trading slid over 5% to test 47 HKD, the session low, before afternoon recovery lifted the close to 48.88 HKD. Public company fundamentals remain sound, with Q1 and Q2 revenues expanding over 24% year-over-year and net margins sustained at 20.7%, complemented by recent wins including a decade-long biosimilar drug order and dual major awards at the 2026 Hong Kong ESG Reporting Awards; however, these positive developments proved insufficient to offset broader market adjustment pressure. Year-to-date performance shows appreciation exceeding 50%, though shares currently trade approximately 16% below the 52-week high of 58 HKD recorded in early October and sit marginally below the 60-day moving average of 49.88 HKD. The current PE ratio of 34.9 reflects elevated valuation multiples.

  5. Nov, 10

    WuXi Biologics closed at HKD 49.62, up 1.43% from the previous close, reflecting sustained market confidence in the biotech CDMO sector. Year-to-date the stock has appreciated 52.49%, while currently trading 14.45% below its 52-week high of HKD 58 recorded in early October. Recent Q2 results demonstrated solid operational performance: operating revenue grew 24.83% year-over-year to HKD 6.81 billion, while operating profit surged 44.25% YoY to HKD 2.15 billion, with net margins stable at 20.7%. Market sentiment has remained constructive regarding the company's CDMO business expansion, particularly following strengthened collaborations with international pharmaceutical partners like Fresenius and recently secured decade-long biosimilar orders. Citi and other institutional analysts have maintained constructive research coverage. The current PE valuation of 35.43x, though moderating from peak levels, remains elevated relative to historical norms; sustaining robust profit growth will prove crucial to justifying the existing valuation.

News

Bullish vs. Bearish — Last 3 Months

22.6k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • J
    Joannee

    Seriously, Singtel stop making my life hard. I need the connectivity. Can't believe they are so terrible. I am cancelling my plan with them and will short it!

    C
    Captain's Watch
    ☕️ Daily Market Talk | March 24, 2026

    Hi guys ☕️ Big news: Alibaba dropping a new chip? SK Hynix goes all in on HBM. Apple teases a big one at WWDC. Singtel tanks 5.4%. CapLand Ascendas REIT goes big. Plus 6 earnings. What's catching your eye? 👇

    LONGBRIDGE 2026/03/24 LONGBRIDGE DAILY MARKET TALK TUESDAY 0000 Alibaba Poised t
  • F
    Fattycat

    I believe Alibaba is going to surprise the market with a major new chip product. 💪🏽

    It is also surprising that no one is talking about yesterday’s gold movement. Gold has never, in history, dropped 10% and then rebounded 10% in a day. The decline itself was the first of its kind in 40 years.

    C
    Captain's Watch
    ☕️ Daily Market Talk | March 24, 2026

    Hi guys ☕️ Big news: Alibaba dropping a new chip? SK Hynix goes all in on HBM. Apple teases a big one at WWDC. Singtel tanks 5.4%. CapLand Ascendas REIT goes big. Plus 6 earnings. What's catching your eye? 👇

    LONGBRIDGE 2026/03/24 LONGBRIDGE DAILY MARKET TALK TUESDAY 0000 Alibaba Poised t
  • C
    Crazy rich

    Singtel -5.4% on outage is a buying opportunity if you believe network reliability is fixable. Core business unchanged

    C
    Captain's Watch
    ☕️ Daily Market Talk | March 24, 2026

    Hi guys ☕️ Big news: Alibaba dropping a new chip? SK Hynix goes all in on HBM. Apple teases a big one at WWDC. Singtel tanks 5.4%. CapLand Ascendas REIT goes big. Plus 6 earnings. What's catching your eye? 👇

    LONGBRIDGE 2026/03/24 LONGBRIDGE DAILY MARKET TALK TUESDAY 0000 Alibaba Poised t